GeoVax Labs (GOVX) Stock Price, News & Analysis

Company Overview

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Key Stats

• Today's Range: $0.99 to $1.07
• 50-Day Range: $0.76 to $1.54
• 52-Week Range: $0.73 to $11.18
• Volume: 272,974 shs
• Average Volume: 538,418 shs
• Market Capitalization: $15.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.10
• Consensus Rating: Buy

GeoVax Labs Stock Analysis - MarketRank™

GeoVax Labs scored higher than 44% of companies evaluated by MarketBeat, and ranked 610th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

GeoVax Labs has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

GeoVax Labs has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GeoVax Labs are expected to grow in the coming year, from ($4.49) to ($1.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GeoVax Labs is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GeoVax Labs is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GeoVax Labs has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.89% of the outstanding shares of GeoVax Labs have been sold short.

Short Interest Ratio / Days to Cover

GeoVax Labs has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GeoVax Labs has recently increased by 8.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GeoVax Labs does not currently pay a dividend.

Dividend Growth

GeoVax Labs does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.89% of the outstanding shares of GeoVax Labs have been sold short.

Short Interest Ratio / Days to Cover

GeoVax Labs has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GeoVax Labs has recently increased by 8.38%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

20 people have searched for GOVX on MarketBeat in the last 30 days. This is an increase of 186% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added GeoVax Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, GeoVax Labs insiders have bought more of their company's stock than they have sold. Specifically, they have bought $33,884.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 1.20% of the stock of GeoVax Labs is held by insiders.

Percentage Held by Institutions

Only 6.09% of the stock of GeoVax Labs is held by institutions.

GOVX Stock Analysis - Frequently Asked Questions

How have GOVX shares performed this year?

GeoVax Labs' stock was trading at $2.47 at the beginning of the year. Since then, GOVX shares have decreased by 57.9% and is now trading at $1.04.
View the best growth stocks for 2025 here.

How were GeoVax Labs' earnings last quarter?

GeoVax Labs, Inc. (NASDAQ:GOVX) issued its quarterly earnings results on Thursday, May, 1st. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.14. The company had revenue of $1.64 million for the quarter, compared to analyst estimates of $0.75 million.
Read the conference call transcript.

When did GeoVax Labs' stock split?

Shares of GeoVax Labs reverse split on the morning of Wednesday, January 31st 2024. The 1-15 reverse split was announced on Wednesday, January 31st 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are GeoVax Labs' major shareholders?

Top institutional investors of GeoVax Labs include Armistice Capital LLC (4.36%) and Jane Street Group LLC (0.17%). Insiders that own company stock include David A Dodd, Mark Reynolds, John N Spencer Jr, John W Sharkey, Randal D Chase and Kelly T Jr Mckee.
View institutional ownership trends.

How do I buy shares of GeoVax Labs?

Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GeoVax Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GeoVax Labs investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), KALA BIO (KALA), Lipocine (LPCN), Fortress Biotech (FBIO) and Ovid Therapeutics (OVID).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 5/20/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GOVX
• CIK: 832489
• Web: www.geovax.com
• Phone: (678) 384-7220
• Fax: 678-384-7281
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.10
• High Stock Price Target: $20.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +967.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-25,970,000.00
• Net Margins: N/A
• Pretax Margin: -787.09%
• Return on Equity: -809.87%
• Return on Assets: -349.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.17
• Quick Ratio: 4.17

Sales & Book Value

• Annual Sales: $5.59 million
• Price / Sales: 2.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.24 per share
• Price / Book: 0.32

Miscellaneous

• Outstanding Shares: 15,194,000
• Free Float: 8,898,000
• Market Cap: $15.80 million
• Optionable: Not Optionable
• Beta: 3.47